<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="en">Diabetes mellitus</journal-title><trans-title-group xml:lang="ru"><trans-title>Сахарный диабет</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM8039</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-8039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Experimental Diabetology</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Экспериментальная диабетология</subject></subj-group></article-categories><title-group><article-title>Echinochrome pigment attenuates diabetic nephropathy in the models of type 1 and type 2 diabetes</article-title><trans-title-group xml:lang="ru"><trans-title>Пигмент эхинохром ослабляет проявления диабетической нефропатии на экспериментальных моделях сахарного диабета 1 и 2 типов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Soliman</surname><given-names>Amel M.</given-names></name><name name-style="western" xml:lang="en"><surname>Soliman</surname><given-names>Amel Mahmoud</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>Professor of Physiology, Zoology Department</p></bio><email xlink:type="simple">soliman.amel5@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Mohamed</surname><given-names>Ayman S.</given-names></name><name name-style="western" xml:lang="en"><surname>Mohamed</surname><given-names>Ayman Saber</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">ayman81125@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Marie</surname><given-names>Mohamed-Assem S.</given-names></name><name name-style="western" xml:lang="en"><surname>Marie</surname><given-names>Mohamed-Assem Said</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">massemmarie@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Каирский университет</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Cairo University</institution><country>Egypt</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>02</day><month>12</month><year>2016</year></pub-date><volume>19</volume><issue>6</issue><fpage>464</fpage><lpage>470</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Soliman A.M., Mohamed A.S., Marie M.S., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Soliman A.M., Mohamed A.S., Marie M.S.</copyright-holder><copyright-holder xml:lang="en">Soliman A.M., Mohamed A.S., Marie M.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/8039">https://www.dia-endojournals.ru/jour/article/view/8039</self-uri><abstract><p>Background. The main complication of diabetes mellitus is diabetic nephropathy in both types, which is a main reason for renal failure. Echinochrome substance present in sea urchin shells and spines and possesses high antioxidant activity.Aim. is to evaluate the ability of Ech to suppress the progression of diabetic complication in kidney.Materials and methods. Thirty-six male Wistar albino rats were divided into two main groups, type 1 diabetes mellitus and type 2 diabetes mellitus. Both groups divided into control, diabetic and echinochrome subgroups. Type 1 diabetes was induced by single dose of streptozotocin (60 mg/kg, i.p), while type 2 was induced by high fat diet for 4 weeks before the injection with streptozotocin (30 mg/kg, i.p). The treated groups were administrated by echinochrome (1mg/kg body weight in 10% DMSO) daily for 4 weeks.Results. Echinochrome groups showed reduction in the concentrations of glucose, malondialdehyde, urea, uric acid and creatinine. While it caused general increase in glutathione-S-transferase, superoxide dismutase, catalase, glutathione reduced, nitric oxide and creatinine clearance. The histopathological investigation showed clear improvement in the kidney architecture.Conclusion. Administration of echinochrome improves renal function and ameliorates renal histopathological changes possibly by improvement of glucose metabolism and inhibition of lipid peroxidation process.</p></abstract><trans-abstract xml:lang="ru"><sec><title>Актуальность</title><p>Актуальность. Одним из главных осложнений сахарного диабета обоих типов является диабетическая нефропатия, которая выступает основной причиной почечной недостаточности. Пигмент эхинохром, содержащийся в раковинах и иголках морских ежей, обладает высокой антиоксидантной активностью.</p></sec><sec><title>Цель</title><p>Цель. Изучить способность эхинохрома замедлять прогрессирование диабетической нефропатии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Тридцать шесть крыс-альбиносов линии Wistar мужского пола были разделены на 2 группы: группа сахарного диабета 1 типа (СД1) и группа сахарного диабета 2 типа (СД2). Обе группы были, в свою очередь, разделены на подгруппы: группу контроля, группу диабета и группу эхинохрома. СД1 у мышей вызывали однократным введением стрептозотоцина (60 мг/кг интраперитонеально), а СД2 — повышенным содержанием жиров в пище в течение 4 недель до введения стрептозотоцина (30 мг/кг интраперитонеально). Экспериментальным группам вводили эхинохром (1 мг/кг в 10% растворе диметилсульфоксида) ежедневно в течение 4 недель.</p></sec><sec><title>Результаты</title><p>Результаты. В группах эхинохрома было отмечено снижение концентрации глюкозы, малондиальдегида, мочевины, мочевой кислоты и креатинина. Было также отмечено повышение уровней глутатион-S-трансферазы, супероксиддисмутазы, каталазы, восстановленного глутатиона, оксида азота и клиренса креатинина. Гистологические исследования показали отчетливое восстановление микроархитектоники почечной ткани.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>эхинохром</kwd><kwd>нефропатия</kwd><kwd>оксидативный стресс</kwd><kwd>почки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>echinochrome- nephropathy</kwd><kwd>oxidative stress</kwd><kwd>kidney</kwd></kwd-group></article-meta></front><body><p>The prevalence of diabetes mellitus (DM) has risen rapidly in the past few years [<xref ref-type="bibr" rid="cit1">1</xref>]. DM is a main cause of morbidity and mortality worldwide [<xref ref-type="bibr" rid="cit2">2</xref>]. It is considering a metabolic disorder characterized by hyperglycemia, which caused by the deficiency in insulin secretion within type 1 diabetes (T1DM), and it is the main a feature of uncontrolled type 2 diabetes (T2DM) along with insulin resistance. Many complications accompanied uncontrolled diabetes include vasculopathy, cardiomyopathy, nephropathy, neuropathy and retinopathy.</p><p>A major complication of DM is diabetic nephropathy (DN) in both type 1 and type 2, which is a main cause of end stage renal disease [<xref ref-type="bibr" rid="cit3">3</xref>]. DN development process is associated with inflammation, renal hypertrophy, and fibrosis [<xref ref-type="bibr" rid="cit1">1</xref>]. DM stimulates significant change in renal architecture, such as severe reduction of glomerular tufts and increasing of Bowman’s spaces. Although a number of factors have been implicated in the pathogenesis of DN include oxidative stress [<xref ref-type="bibr" rid="cit4">4</xref>].</p><p>Chronic hyperglycemia activates production of reactive oxygen species (ROS) through multiple pathways, which collectively contribute to the pathogenesis of DN [<xref ref-type="bibr" rid="cit5">5</xref>]. The effect of ROS includes damage of cell membrane; inactivate endogenous antioxidants, lipid and carbohydrate. Thus, prevention of oxidative stress is the key factor for treatment of DN.</p><p>Streptozotocin (STZ) is well known for its selective beta cell cytotoxicity, which induces DM in rats [<xref ref-type="bibr" rid="cit6">6</xref>]. The animal model of high-fat diet (HFD) which combined with low dose STZ induced diabetes manifests many characteristics of human type 2 diabetes, such as hyperglycemia, hyperlipemia and lack of insulin secretion [<xref ref-type="bibr" rid="cit1">1</xref>].</p><p>Echinochrome (Ech) is pigment extracted from sea urchins which have antioxidant and hypoglycemic activities [<xref ref-type="bibr" rid="cit7">7</xref>]. The aim of the study is to evaluate the ability of Ech to suppress the progression of diabetic complication in kidney</p><sec><title>Materials and methods</title><p>Chemicals and reagents</p><p>Streptozotocin (STZ), sodium pentobarbital and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Biochemical kits were purchased from the Biodiagnistic Company (El Moror St, Dokki, EGY).</p><p>Sea urchin collection</p><p>Sea urchins (Paracentrotus lividus) were collected from the Mediterranean coast of Alexandria (Egypt) and transported to the laboratory packed in ice. The samples were thoroughly washed with sea water to remove sand and overgrowing organisms at the collection site and transported to the laboratory. The collected specimens were immediately shade dried.</p><p>Echinochrome (Ech) extraction</p><p>Pigments in the shells and spines were isolated by the Amarowicz method with slight modifications [<xref ref-type="bibr" rid="cit8">8</xref>]. After removal of the internal organs, the shells and spines were washed with a stream of cold water, air-dried at 4°C for 2 days in the dark and then were grounded. The powders (5 g) were dissolved by gradually adding 10 ml of 6 M HCl. The pigments in the solution were extracted 3 times with the same volume of diethyl ether. The ether layer collected was washed with 5% NaCl until the acid was almost removed. The ether solution including the pigments was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The extract including the polyhydroxylated naphthoquinone pigment was stored at -30°C in the dark.</p><p>Experimental animals</p><p>Male albino Wistar rats (Rattus norvegicus) weighing 140 ± 10 gm for T1DM and 80 ± 10 gm for T2DM were used in this study. The rats were obtained from the National Research Center (NRC, Dokki, Giza). Rats were housed in a temperature and humidity controlled environment and given food and water ad libitum.</p><p>Ethical consideration and field study</p><p>Experimental protocols and procedures used in this study were approved by the Cairo University, Faculty of Science, Institutional Animal Care and Use Committee (IACUC) (Egypt) (CUFS/F/33/14). All the experimental procedures were carried out in accordance with international guidelines for the care and use of laboratory animals.</p><p>Induction of type 1 diabetes mellitus (T1DM)</p><p>All rats were starved for 12 hrs before the experiment, but were allowed free access to water. T1DM was induced by intraperitoneal injection of 60 mg/kg of STZ dissolved in 0.1mol/l sodium citrate buffer at pH 4.5. Blood glucose levels were measured 72 hr after injection of STZ. Rats were starved, but had access to drinking water for 6 hr before blood glucose measurement. Fasting plasma glucose concentrations ≥ 300 mg/100ml were considered diabetic type 1 in this experiment.</p><p>Induction of type 2 diabetes mellitus (T2DM)</p><p>The rats were fed a high fat diet (HFD) with energy of 5.3 kcal/g, comprising 60% calories from fat, 35% from protein and 5% from carbohydrate. After 4 weeks the rats injected intraperitoneally by a single dose of prepared solution of STZ (30 mg/kg dissolved in 0.1mol/l sodium citrate buffer at pH 4.5). After 72 hours, fasting plasma glucose concentrations ≥ 300 mg/100 ml were considered diabetic type 2 in this experiment.</p><p>Experimental design</p><p>After one week of acclimatization, 36 rats were assigned into two main groups; T1DM group (18 rats) and T2DM group (18 rats).</p><p>T1DM rats group divided into 3 subgroups (6 rats/subgroup):</p><p>Control subgroup: After a single dose of citrate buffer (0.1mol/l, i.p), the rats received 1ml (10% DMSO, orally) daily for 4 weeks.</p><p>Diabetic subgroup: After a single dose of STZ (60 mg/kg, i.p), the rats received 1ml (10% DMSO, orally) daily for 4 weeks.</p><p>Ech subgroup: After a single dose of STZ (60 mg/kg, i.p), the rats received 1ml Ech (1mg/kg body weight in 10% DMSO, orally) [<xref ref-type="bibr" rid="cit9">9</xref>] daily for 4 weeks.</p><p>T2DM group divided also into 3 subgroups (6 rats/subgroup):</p><p>Control subgroup: After 4 weeks of normal diets feeding, the rats injected with single dose of citrate buffer (0.1mol/l, i.p) then received 1ml of (10% DMSO, orally) daily for 4 weeks.</p><p>Diabetic subgroup: After 4 weeks of HFD feeding, the rats injected with single dose of STZ (30 mg/kg, i.p) then received 1ml of (10% DMSO, orally) daily for 4 weeks.</p><p>Ech subgroup: After 4 weeks of HFD feeding, the rats injected with single dose of STZ (30 mg/kg, i.p) then received 1ml Ech (1mg/kg in 10% DMSO, orally) daily for 4 weeks.</p><p>Animal handling and specimen collection</p><p>After the end of all experiments, the rats were fully anesthetized with 3% sodium pentobarbital, and the chest was opened. A needle was inserted through the diaphragm and into the heart. Negative pressure was gently applied once the heart had been punctured, and the needle was repositioned as required until blood flowed into the syringe. The blood collected from the rats was separated by centrifugation (3000 rpm, 15 min) to obtain sera which were stored at -80°C for the biochemical measurements. The 24 hr (before killing) urine was collected while rats were housed in metabolism cages.</p><p>Kidney was removed and immediately blotted using filter paper to remove traces of blood. Then it suspended in 10% formal saline for fixation preparatory to histopathological examination.</p><p>Histopathological investigation</p><p>The fixed kidney was washed, dehydrated, and embedded in paraffin wax. They were sectioned at a thickness of 4-5 µm and stained with hematoxylin and eosin (H&amp;E) as routine procedures for histopathological examination.</p><p>Biochemical analyses:</p><p>The serum glucose was estimated by the method of Freund et al [<xref ref-type="bibr" rid="cit10">10</xref>], serum and urine creatinine was estimated by the method of Schirmeister [<xref ref-type="bibr" rid="cit11">11</xref>] urea [<xref ref-type="bibr" rid="cit12">12</xref>] and uric acid [<xref ref-type="bibr" rid="cit13">13</xref>] according to the manufacturer's instructions using Bio-diagnostic kits (Giza, Egypt).</p><p>MDA level is an index of lipid peroxidation and it was estimated by Ohkawa [<xref ref-type="bibr" rid="cit14">14</xref>], glutathione reduced (GSH) [<xref ref-type="bibr" rid="cit15">15</xref>], nitric oxide (NO) [<xref ref-type="bibr" rid="cit16">16</xref>], glutathione-S-transferase (GST) [<xref ref-type="bibr" rid="cit17">17</xref>], superoxide dismutase (SOD) [<xref ref-type="bibr" rid="cit18">18</xref>] and catalase [<xref ref-type="bibr" rid="cit19">19</xref>] were determined in the kidney homogenate supernatant according to the manufactures instructions using Bio-diagnostic kits (Giza, Egypt).</p><p>Statistical analysis</p><p>Values were expressed as means ±SE. The comparisons within groups were evaluated utilizing one way analysis of variance (ANOVA) with Duncan post hoc test was used to compare the group means and p &lt; 0.05 was considered statistically significant. SPSS, for Windows (version 20) was used for the statistical analysis.</p></sec><sec><title>Results</title><p>According to the data represented in table (1), the serum glucose concentration increased significantly (P&lt;0.05) in diabetic rats, as compared to corresponding control groups. While, a significant decrease (P&lt;0.05) was recorded in serum glucose concentration of Ech treated rats, as compared to corresponding diabetic groups (Table 1).</p><p>Table 1. The effect of Ech on blood glucose (mg/dl) of diabetic male rats</p><table-wrap id="table-1"><table><tbody><tr><td>Parameter</td><td>Diabetes type</td><td>Groups</td></tr><tr><td>Control</td><td>Diabetes</td><td>Ech</td></tr><tr><td>Bood glucose (mg/dl)</td><td>T1DM</td><td>91.83±7.14a</td><td>370.67±20.7c</td><td>176.00±14.7b</td></tr><tr><td>T2DM</td><td>109.50±3.00a</td><td>317.67±4.20c</td><td>167.17±22.7b</td></tr></tbody></table></table-wrap><p>The represented data in table (2) showed significant increase (P &lt;0.05) in urine volume, creatinine, urea and uric acid concentrations within the diabetic rats as compared to the corresponding control groups. After 4 weeks of Ech treatment a significant decrease (P&lt;0.05) in urine volume, creatinine, urea and uric acid concentrations was observed as compared to the corresponding diabetic groups (Table 2).</p><p>Table 2. The effect of Ech on kidney function parameters of diabetic male rats in urine</p><table-wrap id="table-2"><table><tbody><tr><td>Parameter</td><td>Diabetes type</td><td>Groups</td></tr><tr><td>Control</td><td>Diabetes</td><td>Ech</td></tr><tr><td>Urine Volume (ml/24hr)</td><td>T1DM</td><td>8.75±0.04a</td><td>45.17±0.10c</td><td>19.75±0.16b</td></tr><tr><td>T2DM</td><td>9.25±0.16a</td><td>36.17±0.24c</td><td>20.33±0.14b</td></tr><tr><td>Urine uric acid(mg/dl)</td><td>T1DM</td><td>82.98±2.34a</td><td>510.05±4.03c</td><td>241.58±3.04b</td></tr><tr><td>T2DM</td><td>98.32±2.25a</td><td>320.67±3.77c</td><td>193.33±3.04b</td></tr><tr><td>Urine urea (g/dl)</td><td>T1DM</td><td>160.33±0.65a</td><td>540.48±3.79b</td><td>170.53±0.11a</td></tr><tr><td>T2DM</td><td>140.50±0.12a</td><td>310.80±0.55c</td><td>200.28±0.39b</td></tr><tr><td>Urine creatinine(mg/dl)</td><td>T1DM</td><td>0.82±0.00a</td><td>6.73±0.24c</td><td>2.03±0.02b</td></tr><tr><td>T2DM</td><td>0.87±0.01a</td><td>1.45±0.00</td><td>1.28±0.02b</td></tr></tbody></table></table-wrap><p>Note: Values are given as mean±SE for 6 rats in each group. Each value not sharing a common letter superscript is significantly different (P&lt;0.05).</p><p>Table (3) revealed that T1DM and T2DM rats showed a significant increase (P &lt; 0.05) in serum creatinine, urea and uric acid concentrations as compared to the corresponding control groups. However creatinine clearance showed a significant decrease (P &lt;0.05) in both types.</p><p>On the other hand, Ech-treated groups showed a significant decrease (P &lt; 0.05) in serum creatinine, urea and uric acid concentrations as compared to the corresponding diabetic groups. While creatinine clearance showed significant increase (P &lt;0.05) in both types of the treated groups (Table 3).</p><p>Table 3. The effect of Ech on kidney function parameters of diabetic male rats in serum</p><table-wrap id="table-3"><table><tbody><tr><td>Parameter</td><td>Diabetes type</td><td>Groups</td></tr><tr><td>Control</td><td>Diabetes</td><td>Ech</td></tr><tr><td>Serum uric acid(mg/dl)</td><td>T1DM</td><td>1.46±0.01</td><td>2.03±0.01c</td><td>1.81±0.03ab</td></tr><tr><td>T2DM</td><td>4.23±0.02ab</td><td>6.24±0.01c</td><td>4.50±0.01ab</td></tr><tr><td>Serum urea(g/dl)</td><td>T1DM</td><td>22.07±0.29a</td><td>47.07±0.75c</td><td>27.83±0.71ab</td></tr><tr><td>T2DM</td><td>26.07±0.33ab</td><td>45.73±0.69c</td><td>30.50±0.69ab</td></tr><tr><td>Serum creatinine(mg/dl)</td><td>T1DM</td><td>1.86±0.07a</td><td>3.29±0.12e</td><td>2.09±0.02bc</td></tr><tr><td>T2DM</td><td>1.74±0.04a</td><td>2.77±0.03d</td><td>2.42±0.01c</td></tr><tr><td>Creatinine clearance(ml/min)</td><td>T1DM</td><td>8.00±0.36a</td><td>3.83±0.03e</td><td>5.00±0.10b</td></tr><tr><td>T2DM</td><td>5.05±0.23a</td><td>0.78±0.04d</td><td>3.47±0.17c</td></tr></tbody></table></table-wrap><p>Note: Values are given as mean±SE for 6 rats in each group. Each value not sharing a common letter superscript is significantly different (P&lt;0.05).</p><p>The represented data in table (4) showed general decreases in GST, SOD, CAT activates and concentrations of GSH and NO in both types of diabetic rats as compared to the corresponding control groups. However MDA concentration was increased significantly (P &lt;0.05). After 4 weeks of Ech treatment there is general increase in GST, SOD, CAT activates and concentrations of GSH and NO rats as compared to the corresponding diabetic groups. While MDA concentration decreased significantly (P &lt;0.05).</p><p>Table 4. The effect of Ech on kidney oxidative stress parameters</p><table-wrap id="table-4"><table><tbody><tr><td>Parameter</td><td>Diabetes type</td><td>Groups</td></tr><tr><td>Control</td><td>Diabetes</td><td>Ech</td></tr><tr><td>MDA(nmol/g. tissue)</td><td>T1DM</td><td>7.29±0.10a</td><td>10.60±0.10b</td><td>8.02±0.06a</td></tr><tr><td>T2DM</td><td>6.34±0.11a</td><td>9.22±0.09b</td><td>7.14±0.09a</td></tr><tr><td>GSH(mg/ g. tissue)</td><td>T1DM</td><td>26.20±0.28b</td><td>21.13±0.16a</td><td>24.13±0.21b</td></tr><tr><td>T2DM</td><td>23.90±0.14b</td><td>20.60±0.09a</td><td>25.17±0.23b</td></tr><tr><td>NO(μmol/L)</td><td>T1DM</td><td>27.80±0.16b</td><td>23.60±0.07a</td><td>27.40±0.35b</td></tr><tr><td>T2DM</td><td>25.40±0.33a</td><td>23.60±0.27a</td><td>35.00±0.19b</td></tr><tr><td>GST(U/ g. tissue)</td><td>T1DM</td><td>4.20±0.02a</td><td>3.76±0.04a</td><td>5.05±0.09c</td></tr><tr><td>T2DM</td><td>4.38±0.08ab</td><td>4.15±0.03a</td><td>4.85±0.07b</td></tr><tr><td>SOD(U/ g. tissue)</td><td>T1DM</td><td>768.75±6.56b</td><td>637.50±18.47a</td><td>750.00±4.07b</td></tr><tr><td>T2DM</td><td>878.32±2.12a</td><td>796.88±5.75a</td><td>835.63±2.68a</td></tr><tr><td>CAT(U/ g. tissue)</td><td>T1DM</td><td>1.66±0.01a</td><td>1.43±0.03a</td><td>1.49±0.02a</td></tr><tr><td>T2DM</td><td>1.89±0.01b</td><td>1.53±0.02a</td><td>1.80±0.03ab</td></tr></tbody></table></table-wrap><p>Note: Values are given as mean±SE for 6 rats in each group. Each value not sharing a common letter superscript is significantly different (P&lt;0.05).</p><p>Histopathological investigation of kidney</p><p>Microscopic examination of the control kidney sections showed normal histoarchitecture with normal glomerulus and Bowman’s capsule (Fig. 1 A,B). On the other hand, the histopathological study of kidney of type 1 and type 2 diabetic rats showed severe degeneration in glomerulus with deformed renal tissue architecture (Fig. 1 C,D). Whereas the treatment with Ech caused marked regeneration in glomerulus and Bowman’s capsule with normal renal tissue architecture (Fig. 1 E,F).</p><fig id="fig-1"><graphic xlink:href="diaendo-19-6-g001.png"><uri content-type="original_file">/public/site/images/letum/сд11.png</uri></graphic></fig><p>Figure 1: Photomicrograph of hematoxylin and eosin stained kidney sections from (A&amp;B) control rats; (C&amp;D) diabetic rats and (E&amp;F) Ech-treated rats (H&amp;E × 400).</p><p>The morphometric data represented that, renal corpuscle, glomerulus and tubular areas of the diabetic rats were increased significantly as compared to control rats (Table 5). Also, abundant mesangial cells were present in the glomerulus of diabetic rats. On the other hand, Ech-treated groups showed reduction in renal corpuscle, glomerulus and tubular areas as long as mesangial cells number as compared to diabetic rats (Table 5).</p><p>Table 5. Effect of Ech on morphometric parameters of diabetic male rats</p><table-wrap id="table-5"><table><tbody><tr><td>Parameter</td><td>Diabetes type</td><td>Groups</td></tr><tr><td>Control</td><td>Diabetes</td><td>Ech</td></tr><tr><td>Renal corpuscle area (µm2)</td><td>T1DM</td><td>10346±145a</td><td>17110±178b</td><td>12493±199a</td></tr><tr><td>T2DM</td><td>8918±155a</td><td>12767±188c</td><td>9620±111b</td></tr><tr><td>Glomerulus area (µm2)</td><td>T1DM</td><td>5917±80a</td><td>7904±100c</td><td>6999±90b</td></tr><tr><td>T2DM</td><td>4172±144a</td><td>7043±90c</td><td>4886±110b</td></tr><tr><td>Distal tubule area (µm2)</td><td>T1DM</td><td>114±20a</td><td>661±70c</td><td>463±64b</td></tr><tr><td>T2DM</td><td>383±50a</td><td>528±71b</td><td>464±40a</td></tr><tr><td>Proximal tubule area (µm2)</td><td>T1DM</td><td>222±55a</td><td>643±99b</td><td>223±85a</td></tr><tr><td>T2DM</td><td>210±30a</td><td>467±68b</td><td>229±49a</td></tr><tr><td>Number of cells/glomerulus</td><td>T1DM</td><td>60±4a</td><td>76±8b</td><td>66±3a</td></tr><tr><td>T2DM</td><td>43±3a</td><td>64±6b</td><td>48±2a</td></tr></tbody></table></table-wrap><p>Note: the morphometric study was performed in 3 µm thick renal sections stained with hematoxylin and eosin. Fifty glomeruli were analyzed per rat.</p></sec><sec><title>Discussion</title><p>Diabetes mellitus (DM) is characterized by absolute or relative deficiencies in insulin secretion, insulin action or both. Diabetic nephropathy (DN) model was established by the significant increase in serum and urine urea, uric acid and creatinine in addition to the significant decrease in creatinine clearance in type 1 diabetes (T1DM) and type 2 diabetes (T2DM) groups. The biochemical changes were confirmed with a histopathological investigation, which detected a marked damage in renal structure showing congestion and severe degeneration in tubular and glomerulus. The most common features of vascular lesions in diabetic mellitus are renal glomerular degeneration along with tubular and interstitial abnormalities [<xref ref-type="bibr" rid="cit20">20</xref>]. Distal and Proximal tubule areas were found to be significantly higher in the diabetic rats which may indicate proliferation and hypertrophy in the glomerular and tubular regions. The hyperglycemia condition induce proliferation or hypertrophy in renal structures especially in the glomerular mesangium [<xref ref-type="bibr" rid="cit21">21</xref>].In addition the high glucose level lead to increase number of glomerular mesangial cells and interstitial alterations [<xref ref-type="bibr" rid="cit22">22</xref>].Increased the areas renal corpuscle and glomerulus may due to fill the urinary space by glomerular capillaries causing sever reduction in the capsular space [<xref ref-type="bibr" rid="cit23">23</xref>].</p><p>The current investigation revealed that, induction of diabetes resulted in elevation of serum and urine creatinine concentration whereas creatinine clearance decreased. High levels of creatinine indicate several disturbances in kidney [<xref ref-type="bibr" rid="cit24">24</xref>]. In addition, this increase in serum creatinine may be due to the hepatic damage, which evolved into a stage with features of hepatorenal syndrome [<xref ref-type="bibr" rid="cit25">25</xref>]. Furthermore, decrease creatinine clearance reflecting kidney function impairment in diabetic patient.</p><p>The most frequently determined clinical indices for estimating renal function depends upon concentration of urea in the serum. The current investigation revealed that, induction of diabetes resulted in elevation of serum and urine urea concentration. The pathogenesis of diabetic nephropathy are related to chronic hyperglycemia and hemodynamic alterations in renal microcirculation and structural changes in glomerulus as evidenced by the significant elevation in urea level [<xref ref-type="bibr" rid="cit26">26</xref>].</p><p>Negative nitrogen balance is manifested in diabetic rats associated with enhanced proteolysis in muscle and other tissues. Impaired balance of nitrogen coupled with lowered protein synthesis leads to increased concentrations of urea indicates progressive renal damage in diabetic rats [<xref ref-type="bibr" rid="cit27">27</xref>].</p><p>Hyperuricemia is a common finding in patients with metabolic syndrome or its components, such as central obesity and hypertriglyceridemia [<xref ref-type="bibr" rid="cit28">28</xref>]. Also, increase serum uric acid levels were associated with elevated levels of serum markers of hepatic necroinflammation (ALAT and GGT) and it might be a risk factor for the incidence of chronic liver disease level [<xref ref-type="bibr" rid="cit29">29</xref>].In addition, an increase in uric acid could relate to oxidative damage [<xref ref-type="bibr" rid="cit30">30</xref>].</p><p>Oxidative stress plays an important role in the development and progression of DN [<xref ref-type="bibr" rid="cit31">31</xref>]. Excessive oxidative stress in the vascular and cellular tissue can lead to dysfunction of endothelial cell [<xref ref-type="bibr" rid="cit3">3</xref>]. Thus, DM is more susceptible to kidney injuries and reduction of kidney function. In the present study the oxidative stress condition was established in the diabetic groups by the increase production of malondialdehyde (MDA) and the deficiency in the anti-oxidant system includes glutathione reduced (GSH), glutathione-S-transferase (GST), superoxide dismutase (SOD) and catalase (CAT). Hyperglycemia causes the production of reactive oxygen species (ROS), leads to reduction-oxidation imbalance, which resulting in oxidative stress condition [<xref ref-type="bibr" rid="cit5">5</xref>]. Oral administration of Ech caused significant decrease in kidney MDA levels and significant increase in the antioxidant system of the diabetic rats.</p><p>Nitric oxide (NO) plays numerous physiological functions in the kidney, including control of renal and glomerular hemodynamics [<xref ref-type="bibr" rid="cit32">32</xref>]. NO concentration decreased significantly in both diabetic groups. This decrease contributes in the chronic kidney disease [<xref ref-type="bibr" rid="cit32">32</xref>]. Many experimental and clinical evidences mention that, renal nitric oxide synthase (NOS) expression and activity are increased at early diabetes; however, they are decreased at prolonged diabetes leading to vascular NO deficiency, which may induce the progression of DN [<xref ref-type="bibr" rid="cit33">33</xref>].</p><p>On the other hand, NO concentration increased in Ech-treated groups. This increase related to the increase in insulin concentration, where many studies have indicated that insulin activates NOS by protein kinase B (PKB)-mediated phosphorylation in endothelial cells [<xref ref-type="bibr" rid="cit34">34</xref>].</p></sec><sec><title>Conclusion</title><p>Administration of echinochrome improves renal function and ameliorates renal histopathological changes possibly by improvement of glucose metabolism and inhibition of lipid peroxidation process.</p></sec><sec><title>Additional information</title><p>Compliance with ethical standards:</p><p>No conflict of interested. The authors did not receive any fund for this work.</p><p>Research involving animals:</p><p>Experimental protocols and procedures used in this study were approved by the Cairo University, Faculty of Science, Institutional Animal Care and Use Committee (IACUC) (Egypt) (CUFS/F/33/14). All the experimental procedures were carried out in accordance with international guidelines for the care and use of laboratory animals.</p></sec></body><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yao L, Li L, Li X, et al. The anti-inflammatory and antifibrotic effects of Coreopsis tinctoria Nutt on high-glucose-fat diet and streptozotocin-induced diabetic renal damage in rats. BMC Complement Altern Med. 2015;15:314. doi: 10.1186/s12906-015-0826-x</mixed-citation><mixed-citation xml:lang="en">Yao L, Li L, Li X, et al. The anti-inflammatory and antifibrotic effects of Coreopsis tinctoria Nutt on high-glucose-fat diet and streptozotocin-induced diabetic renal damage in rats. BMC Complement Altern Med. 2015;15:314. doi: 10.1186/s12906-015-0826-x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Toma A, Makonnen E, Mekonnen Y, et al. Antidiabetic activities of aqueous ethanol and n-butanol fraction of Moringa stenopetala leaves in streptozotocin-induced diabetic rats. BMC Complement Altern Med. 2015;15:242. doi: 10.1186/s12906-015-0779-0</mixed-citation><mixed-citation xml:lang="en">Toma A, Makonnen E, Mekonnen Y, et al. Antidiabetic activities of aqueous ethanol and n-butanol fraction of Moringa stenopetala leaves in streptozotocin-induced diabetic rats. BMC Complement Altern Med. 2015;15:242. doi: 10.1186/s12906-015-0779-0</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tian W, Lei H, Guan R, et al. Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Drug Des Devel Ther. 2015;9:5147-5157. doi: 10.2147/DDDT.S90060</mixed-citation><mixed-citation xml:lang="en">Tian W, Lei H, Guan R, et al. Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Drug Des Devel Ther. 2015;9:5147-5157. doi: 10.2147/DDDT.S90060</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130-143. doi: 10.1016/j.semnephrol.2007.01.006</mixed-citation><mixed-citation xml:lang="en">Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130-143. doi: 10.1016/j.semnephrol.2007.01.006</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang S, Xu H, Yu X, et al. Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model. Int J Clin Exp Med. 2015;8(4):6388-6396.</mixed-citation><mixed-citation xml:lang="en">Zhang S, Xu H, Yu X, et al. Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model. Int J Clin Exp Med. 2015;8(4):6388-6396.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mitra SK, Gopumadhavan S, Muralidhar TS, et al. Effect of a herbomineral preparation D-400 in streptozotocin-induced diabetic rats. J Ethnopharmacol. 1996;54(1):41-46. doi: 10.1016/0378-8741(96)01439-0</mixed-citation><mixed-citation xml:lang="en">Mitra SK, Gopumadhavan S, Muralidhar TS, et al. Effect of a herbomineral preparation D-400 in streptozotocin-induced diabetic rats. J Ethnopharmacol. 1996;54(1):41-46. doi: 10.1016/0378-8741(96)01439-0</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mohamed AS, Soliman AM, Marie MA. Mechanisms of echinochrome potency in modulating diabetic complications in liver. Life Sci. 2016;151:41-49. doi: 10.1016/j.lfs.2016.03.007</mixed-citation><mixed-citation xml:lang="en">Mohamed AS, Soliman AM, Marie MA. Mechanisms of echinochrome potency in modulating diabetic complications in liver. Life Sci. 2016;151:41-49. doi: 10.1016/j.lfs.2016.03.007</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Amarowicz R, Synowiecki J, Shahidi F. Sephadex LH-20 separation of pigments from shells of red sea urchin (Strongylocentrotus franciscanus). Food Chemistry. 1994;51(2):227-229. doi: 10.1016/0308-8146(94)90262-3</mixed-citation><mixed-citation xml:lang="en">Amarowicz R, Synowiecki J, Shahidi F. Sephadex LH-20 separation of pigments from shells of red sea urchin (Strongylocentrotus franciscanus). Food Chemistry. 1994;51(2):227-229. doi: 10.1016/0308-8146(94)90262-3</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lennikov A, Kitaichi N, Noda K, et al. Amelioration of endotoxin-induced uveitis treated with the sea urchin pigment echinochrome in rats. Mol Vis. 2014;20:171-177.</mixed-citation><mixed-citation xml:lang="en">Lennikov A, Kitaichi N, Noda K, et al. Amelioration of endotoxin-induced uveitis treated with the sea urchin pigment echinochrome in rats. Mol Vis. 2014;20:171-177.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Freund A, Johnson SB, Rosenbloom A, et al. Subjective Symptoms, Blood Glucose Estimation, and Blood Glucose Concentrations in Adolescents With Diabetes. Diabetes Care. 1986;9(3):236-243. doi: 10.2337/diacare.9.3.236</mixed-citation><mixed-citation xml:lang="en">Freund A, Johnson SB, Rosenbloom A, et al. Subjective Symptoms, Blood Glucose Estimation, and Blood Glucose Concentrations in Adolescents With Diabetes. Diabetes Care. 1986;9(3):236-243. doi: 10.2337/diacare.9.3.236</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schirmeister J, Man NK, Hallauer W, Gropp H. [Discrepancy in serum urea and creatinine concentrations following acute renal failure]. Dtsch Med Wochenschr. 1969;94(10):482-485. doi: 10.1055/s-0028-1108975</mixed-citation><mixed-citation xml:lang="en">Schirmeister J, Man NK, Hallauer W, Gropp H. [Discrepancy in serum urea and creatinine concentrations following acute renal failure]. Dtsch Med Wochenschr. 1969;94(10):482-485. doi: 10.1055/s-0028-1108975</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fawcett JK, Scott JE. A Rapid and Precise Method for the Determination of Urea. J Clin Pathol. 1960;13(2):156-159. doi: 10.1136/jcp.13.2.156</mixed-citation><mixed-citation xml:lang="en">Fawcett JK, Scott JE. A Rapid and Precise Method for the Determination of Urea. J Clin Pathol. 1960;13(2):156-159. doi: 10.1136/jcp.13.2.156</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. The Analyst. 1972;97(1151):142. doi: 10.1039/an9729700142</mixed-citation><mixed-citation xml:lang="en">Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. The Analyst. 1972;97(1151):142. doi: 10.1039/an9729700142</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal.Biochem. 1979;95(2):351-358. doi: 10.1016/0003-2697(79)90738-3</mixed-citation><mixed-citation xml:lang="en">Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal.Biochem. 1979;95(2):351-358. doi: 10.1016/0003-2697(79)90738-3</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882-888.</mixed-citation><mixed-citation xml:lang="en">Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882-888.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Montgomery H, Dymock JF. Determination of nitrite in water. The Analyst. 1961;86(102): 414.</mixed-citation><mixed-citation xml:lang="en">Montgomery H, Dymock JF. Determination of nitrite in water. The Analyst. 1961;86(102): 414.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249(22):7130-7139.</mixed-citation><mixed-citation xml:lang="en">Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249(22):7130-7139.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nishikimi M, Appaji Rao N, Yagi K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem. Bioph. Res. Common. 1972;46(2):849-854. doi: 10.1016/s0006-291x(72)80218-3</mixed-citation><mixed-citation xml:lang="en">Nishikimi M, Appaji Rao N, Yagi K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem. Bioph. Res. Common. 1972;46(2):849-854. doi: 10.1016/s0006-291x(72)80218-3</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Aebi H. Catalase in vitro. Methods enzymol. 1984;105:121-126. doi: 10.1016/s0076-6879(84)05016-3</mixed-citation><mixed-citation xml:lang="en">Aebi H. Catalase in vitro. Methods enzymol. 1984;105:121-126. doi: 10.1016/s0076-6879(84)05016-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney International. 1994;46(3):797-806. doi: 10.1038/ki.1994.335</mixed-citation><mixed-citation xml:lang="en">Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney International. 1994;46(3):797-806. doi: 10.1038/ki.1994.335</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Onarliogu B, Gürsoy E. Renal ultrastructure in experimental diabetes mellitus. Tr J Med Sci. 1990;(14): 409 - 415.</mixed-citation><mixed-citation xml:lang="en">Onarliogu B, Gürsoy E. Renal ultrastructure in experimental diabetes mellitus. Tr J Med Sci. 1990;(14): 409 - 415.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Seyer-Hansen K, Hansen J, Gundersen HJG. Renal hypertrophy in experimental diabetes. Diabetologia. 1980;18(6). doi: 10.1007/bf00261707</mixed-citation><mixed-citation xml:lang="en">Seyer-Hansen K, Hansen J, Gundersen HJG. Renal hypertrophy in experimental diabetes. Diabetologia. 1980;18(6). doi: 10.1007/bf00261707</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">BULUT HE, ONARLIOĞLU B, KALOĞLU C, et al. Effects of experimental diabetes and insulin treatment on rabbit renal morphology: a quantitative and qualitative study. Tr J Med Sci. 2001;31(3):209-216.</mixed-citation><mixed-citation xml:lang="en">BULUT HE, ONARLIOĞLU B, KALOĞLU C, et al. Effects of experimental diabetes and insulin treatment on rabbit renal morphology: a quantitative and qualitative study. Tr J Med Sci. 2001;31(3):209-216.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Maxine M, Benjamin B. Outline of veterinary clinical pathology. Colorado State University Rekha Printers, New Delhi OpenURL. 1985.</mixed-citation><mixed-citation xml:lang="en">Maxine M, Benjamin B. Outline of veterinary clinical pathology. Colorado State University Rekha Printers, New Delhi OpenURL. 1985.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol. 2000;32:157-170. doi: 10.1016/s0168-8278(00)80423-7</mixed-citation><mixed-citation xml:lang="en">Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol. 2000;32:157-170. doi: 10.1016/s0168-8278(00)80423-7</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bennet J, Braunwald E, Fauci A, et al. Harrison’s principles of internal medicine. Harrison’s Principles of Internal Medicine. 2001.</mixed-citation><mixed-citation xml:lang="en">Bennet J, Braunwald E, Fauci A, et al. Harrison’s principles of internal medicine. Harrison’s Principles of Internal Medicine. 2001.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Veeramani C, Pushpavalli G, Pugalendi KV. Antihyperglycaemic effect of Cardiospermum halicacabum Linn. leaf extract on STZ-induced diabetic rats. J Appl Biomed. 2008;6(1):19-26.</mixed-citation><mixed-citation xml:lang="en">Veeramani C, Pushpavalli G, Pugalendi KV. Antihyperglycaemic effect of Cardiospermum halicacabum Linn. leaf extract on STZ-induced diabetic rats. J Appl Biomed. 2008;6(1):19-26.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19(10):1055-1062. doi: 10.1016/j.amjhyper.2006.02.014</mixed-citation><mixed-citation xml:lang="en">Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19(10):1055-1062. doi: 10.1016/j.amjhyper.2006.02.014</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Baghel M, Modala S, Kumar P, et al. Correlation of creatinine clearance and urine microalbumin in type 2 diabetes mellitus. Int. J. Basic. Appl. Med. Sci. 2014; 4(2):182-186.</mixed-citation><mixed-citation xml:lang="en">Baghel M, Modala S, Kumar P, et al. Correlation of creatinine clearance and urine microalbumin in type 2 diabetes mellitus. Int. J. Basic. Appl. Med. Sci. 2014; 4(2):182-186.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63(3):976-981. doi: 10.2337/db13-1396</mixed-citation><mixed-citation xml:lang="en">Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63(3):976-981. doi: 10.2337/db13-1396</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dave G, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol (Noisy-le-grand). 2007;53(5):68-78.</mixed-citation><mixed-citation xml:lang="en">Dave G, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol (Noisy-le-grand). 2007;53(5):68-78.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Dellamea B, Leitão C, Friedman R, Canani L. Nitric oxide system and diabetic nephropathy. Diabetology &amp; Metabolic Syndrome. 2014;6(1):17. doi: 10.1186/1758-5996-6-17</mixed-citation><mixed-citation xml:lang="en">Dellamea B, Leitão C, Friedman R, Canani L. Nitric oxide system and diabetic nephropathy. Diabetology &amp; Metabolic Syndrome. 2014;6(1):17. doi: 10.1186/1758-5996-6-17</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res. 2014;2014:590541. doi: 10.1155/2014/590541</mixed-citation><mixed-citation xml:lang="en">Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res. 2014;2014:590541. doi: 10.1155/2014/590541</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Salt IP, Morrow VA, Brandie FM, et al. High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem. 2003;278(21):18791-18797. doi: 10.1074/jbc.M210618200</mixed-citation><mixed-citation xml:lang="en">Salt IP, Morrow VA, Brandie FM, et al. High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem. 2003;278(21):18791-18797. doi: 10.1074/jbc.M210618200</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
